247 related articles for article (PubMed ID: 36961210)
21. Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening pipeline and in-vitro validation assays.
Gupta Y; Maciorowski D; Zak SE; Jones KA; Kathayat RS; Azizi SA; Mathur R; Pearce CM; Ilc DJ; Husein H; Herbert AS; Bharti A; Rathi B; Durvasula R; Becker DP; Dickinson BC; Dye JM; Kempaiah P
Methods; 2021 Nov; 195():57-71. PubMed ID: 33453392
[TBL] [Abstract][Full Text] [Related]
22. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
23. Identifying non-nucleoside inhibitors of RNA-dependent RNA-polymerase of SARS-CoV-2 through per-residue energy decomposition-based pharmacophore modeling, molecular docking, and molecular dynamics simulation.
Aziz S; Waqas M; Mohanta TK; Halim SA; Iqbal A; Ali A; Khalid A; Abdalla AN; Khan A; Al-Harrasi A
J Infect Public Health; 2023 Apr; 16(4):501-519. PubMed ID: 36801630
[TBL] [Abstract][Full Text] [Related]
24. Fourteen immunomodulatory alkaloids and two prenylated phenylpropanoids with dual therapeutic approach for COVID-19: molecular docking and dynamics studies.
Omar R; Abd El-Salam M; Elsbaey M; Hassan M
J Biomol Struct Dyn; 2024 Mar; 42(5):2298-2315. PubMed ID: 37116054
[TBL] [Abstract][Full Text] [Related]
25. Identification of repurposing therapeutics toward SARS-CoV-2 main protease by virtual screening.
Sanachai K; Somboon T; Wilasluck P; Deetanya P; Wolschann P; Langer T; Lee VS; Wangkanont K; Rungrotmongkol T; Hannongbua S
PLoS One; 2022; 17(6):e0269563. PubMed ID: 35771802
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and biological evaluation of novel 3C-like protease inhibitors as lead compounds against SARS-CoV-2.
Yan Y; Liu H; Wu D; Gu Z; Guo W; Yao H; Lin K; Li X
Future Med Chem; 2024; 16(9):887-903. PubMed ID: 38618977
[TBL] [Abstract][Full Text] [Related]
27. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
28. Elucidation of the inhibitory activity of plant-derived SARS-CoV inhibitors and their potential as SARS-CoV-2 inhibitors.
Bello M; Hasan MK
J Biomol Struct Dyn; 2022; 40(20):9992-10004. PubMed ID: 34121618
[TBL] [Abstract][Full Text] [Related]
29. Exploring potential SARS-CoV-2 Mpro non-covalent inhibitors through docking, pharmacophore profile matching, molecular dynamic simulation, and MM-GBSA.
Shi Y; Dong L; Ju Z; Li Q; Cui Y; Liu Y; He J; Ding X
J Mol Model; 2023 Apr; 29(5):138. PubMed ID: 37055578
[TBL] [Abstract][Full Text] [Related]
30. QSAR, molecular docking, molecular dynamics and MM-GBSA approach for identification of prospective benzotriazole-based SARS-CoV 3CL protease inhibitors.
D'Souza S; Balaji S; K V P
J Biomol Struct Dyn; 2022; 40(24):14247-14261. PubMed ID: 34877897
[TBL] [Abstract][Full Text] [Related]
31. Computational Screening of Inhibitory Compounds for SARS-Cov-2 3CL Protease with a Database Consisting of Approved and Investigational Chemicals.
Miwa K; Guo Y; Hata M; Yamamoto N; Hoshino T
Chem Pharm Bull (Tokyo); 2023; 71(5):360-367. PubMed ID: 37121686
[TBL] [Abstract][Full Text] [Related]
32. Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study.
Ancy I; Sivanandam M; Kumaradhas P
J Biomol Struct Dyn; 2021 Sep; 39(15):5368-5375. PubMed ID: 32627689
[TBL] [Abstract][Full Text] [Related]
33. A new glimpse on the active site of SARS-CoV-2 3CLpro, coupled with drug repurposing study.
Novak J; Potemkin VA
Mol Divers; 2022 Oct; 26(5):2631-2645. PubMed ID: 35001230
[TBL] [Abstract][Full Text] [Related]
34. Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease.
Kandeel M; Abdelrahman AHM; Oh-Hashi K; Ibrahim A; Venugopala KN; Morsy MA; Ibrahim MAA
J Biomol Struct Dyn; 2021 Sep; 39(14):5129-5136. PubMed ID: 32597315
[TBL] [Abstract][Full Text] [Related]
35. Aminoglycosides as potential inhibitors of SARS-CoV-2 main protease: an in silico drug repurposing study on FDA-approved antiviral and anti-infection agents.
Ahmed MZ; Zia Q; Haque A; Alqahtani AS; Almarfadi OM; Banawas S; Alqahtani MS; Ameta KL; Haque S
J Infect Public Health; 2021 May; 14(5):611-619. PubMed ID: 33866129
[TBL] [Abstract][Full Text] [Related]
36. Identification of structural scaffold from interbioscreen (IBS) database to inhibit 3CLpro, PLpro, and RdRp of SARS-CoV-2 using molecular docking and dynamic simulation studies.
Patil VR; Dhote AM; Patil R; Amnerkar ND; Lokwani DK; Ugale VG; Charbe NB; Firke SD; Chaudhari P; Shah SK; Mehta CH; Nayak UY; Khadse SC
J Biomol Struct Dyn; 2023; 41(22):13168-13179. PubMed ID: 36757134
[TBL] [Abstract][Full Text] [Related]
37. Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study.
Wang J
J Chem Inf Model; 2020 Jun; 60(6):3277-3286. PubMed ID: 32315171
[TBL] [Abstract][Full Text] [Related]
38. Identification of potent COVID-19 main protease inhibitors by loading of favipiravir on Mg
Al-Shuaeeb RAA; Abd El-Mageed HR; Ahmed SA; Mohamed HS; Hamza ZS; Rafi MO; Rahman MS
J Biomol Struct Dyn; 2023; 41(21):11437-11449. PubMed ID: 36591698
[TBL] [Abstract][Full Text] [Related]
39. Computational studies indicated the effectiveness of human metabolites against SARS-Cov-2 main protease.
Roy R; Sk MF; Tanwar O; Kar P
Mol Divers; 2023 Aug; 27(4):1587-1602. PubMed ID: 35978064
[TBL] [Abstract][Full Text] [Related]
40. Identification of a novel dual-target scaffold for 3CLpro and RdRp proteins of SARS-CoV-2 using 3D-similarity search, molecular docking, molecular dynamics and ADMET evaluation.
Aouidate A; Ghaleb A; Chtita S; Aarjane M; Ousaa A; Maghat H; Sbai A; Choukrad M; Bouachrine M; Lakhlifi T
J Biomol Struct Dyn; 2021 Aug; 39(12):4522-4535. PubMed ID: 32552534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
